公开(公告)号：US20140155330A1

公开(公告)日：2014-06-05

申请号：US14177840

申请日：2014-02-11

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Adi Kimchi ,  Assaf Rubinstein

IPC: C07K14/47 ,  G01N33/566 ,  G01N33/574

CPC classification number: C07K14/4747 ,  G01N33/566 ,  G01N33/5748

Abstract: Peptides, compositions and methods for modulating apoptosis, useful for treating diseases or disorders characterized by dysregulated apoptosis, such as cancer or neurodegenerative diseases. Screening methods for identifying agents that mediate apoptosis by regulating Atg12 binding to Bcl-2 family members.

Abstract translation: 用于调节凋亡的肽，组合物和方法，其可用于治疗以失调性细胞凋亡为特征的疾病或病症，例如癌症或神经变性疾病。 通过调节Atg12结合Bcl-2家族成员来鉴定介导凋亡的药剂的筛选方法。

公开(公告)号：US08716228B2

公开(公告)日：2014-05-06

申请号：US13322713

申请日：2010-05-27

Applicant: Michal Eisenbach-Schwartz ,  Gil M Lewitus ,  Michal Cardon-Yaakov ,  Noga Ron-Harel

Inventor： Michal Eisenbach-Schwartz ,  Gil M Lewitus ,  Michal Cardon-Yaakov ,  Noga Ron-Harel

IPC: A61K38/00

CPC classification number: A61K38/22

Abstract: Use of a GPR54 agonist or antagonist for the treatment of a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, and/or for treatment of depression, and/or for improving cognitive function is disclosed. In particular, the invention relates to the use of kisspeptin or a peptide thereof for the treatment of schizophrenia.

Abstract translation: 公开了使用GPR54激动剂或拮抗剂治疗与感觉门控功能的损害有关的疾病或病症，和/或用于治疗抑郁症和/或改善认知功能的疾病或病症。 特别地，本发明涉及kisspeptin或其肽在治疗精神分裂症中的用途。

公开(公告)号：US20140121352A1

公开(公告)日：2014-05-01

申请号：US14146396

申请日：2014-01-02

Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.

Inventor： YORAM SHECHTER ,  MATITYAHU FRIDKIN ,  HAIM TSUBERY

IPC: A61K47/48

CPC classification number: A61K47/60 ,  A61K31/7036 ,  A61K38/1709 ,  A61K38/212 ,  A61K38/22 ,  A61K38/2242 ,  A61K38/2278 ,  A61K38/26 ,  A61K38/27 ,  A61K38/28 ,  A61K47/54 ,  A61K47/545 ,  C07D207/404 ,  C07D207/416 ,  C07D207/452 ,  C07D403/12

Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.

Abstract translation: 可逆的聚乙二醇化药物通过衍生自选自氨基，羟基，巯基，磷酸酯和/或羧基的药物的游离官能团与对温和碱性条件敏感的基团如9-芴基甲氧基羰基（Fmoc）或2-磺基-9-芴基甲氧基羰基 （FMS），连接有PEG部分的基团。 在这些聚乙二醇化药物中，PEG部分和药物残留物不直接相互连接，而是两个残基都连接到对碱基高度敏感并在生理条件下可去除的支架Fmoc或FMS结构的不同位置。 药物优选是含有氨基的药物，最优选低分子量或中等分子量的肽和蛋白质。 提供了类似的分子，其中蛋白质载体或另一种聚合物载体取代了PEG部分。

公开(公告)号：US20140088293A1

公开(公告)日：2014-03-27

申请号：US14093562

申请日：2013-12-02

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Avigdor SCHERZ ,  Oksana Shlyk-Kerner ,  IIan Samish ,  David Kaftan ,  Jorge Dinamarca

IPC: C07K14/405

CPC classification number: C07K14/405 ,  C07K14/195

Abstract: An isolated polynucleotide is provided. The isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide of a Type II reaction center of a photosynthetic organism, the nucleic acid sequence being capable of imparting the type II reaction center with an activity under a temperature range different than that of the type II reaction center endogenous to the photosynthetic organism. Also provided are methods of using the sequences for generating photosynthetic organisms or tailor-made thermotolerance.

Abstract translation: 提供了分离的多核苷酸。 分离的多核苷酸包含编码光合生物的II型反应中心的多肽的核酸序列，所述核酸序列能够使II型反应中心在不同于II型反应的温度范围内具有活性 对光合生物体内生的中心。 还提供了使用序列产生光合生物或定制耐热性的方法。

公开(公告)号：US20140086917A1

公开(公告)日：2014-03-27

申请号：US14118243

申请日：2012-05-16

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michael Sela ,  Yosef Yarden ,  Bilha Schechter ,  Ruth Maron

IPC: A61K39/395 ,  A61N5/10

CPC classification number: A61K39/39558 ,  A61K2039/505 ,  A61K2039/507 ,  A61N5/10 ,  C07K16/2863 ,  C07K16/32

Abstract: An article-of-manufacture is provided. The article-of-manufacture comprises a packaging material identified for treating cancer, packaging: (i) an anti-EGFR antibody comprising the CDR sequences of anti EGFR 565 (CNCM Deposit Number I-4262); and (ii) an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L431 (CNCM Deposit Number I-4115), anti ErbB-2 L26 (CNCM Deposit Number I-4113) or anti ErbB-2 N12 (CNCM Deposit Number I-4112), or (iii) an anti-EGFR antibody comprising the CDR sequences of anti EGFR 111 (CNCM Deposit Number I-4261); and (iv) an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L431 (CNCM Deposit Number I-4115). Also provided are pharmaceutical compositions and methods of using the above antibodies as well as other antibody combinations for the treatment of cancer.

Abstract translation: 提供制造品。 制品包括被鉴定用于治疗癌症的包装材料，包装：（i）包含抗EGFR 565（CNCM保藏号I-4262）的CDR序列的抗EGFR抗体; 和（ii）抗ErbB-2抗体，其包含抗ErbB-2 L431（CNCM保藏号I-4115），抗ErbB-2 L26（CNCM保藏号I-4113）或抗ErbB-2 N12 CNCM保藏号I-4112），或（iii）包含抗EGFR 111（CNCM存放号I-4261）的CDR序列的抗EGFR抗体; 和（iv）包含抗ErbB-2 L431（CNCM保藏号I-4115）的CDR序列的抗ErbB-2抗体。 还提供了药物组合物和使用上述抗体以及用于治疗癌症的其它抗体组合的方法。

公开(公告)号：US20140066490A1

公开(公告)日：2014-03-06

申请号：US13966337

申请日：2013-08-14

Applicant: YEDA Research and Development Co. Ltd.

Inventor： Ehud Y. SHAPIRO ,  Maya KANAN-HANUM ,  Yehonatan DOUEK ,  Rivka ADAR

IPC: C12N15/113 ,  C12N15/10

CPC classification number: C12N15/1136 ,  B82Y10/00 ,  C12N15/1089 ,  C12N15/111 ,  C12N15/1135 ,  C12N2310/127 ,  C12N2310/3519 ,  C12N2310/531 ,  C12N2320/13 ,  C12N2320/50 ,  C12N2330/31 ,  G06N3/123 ,  G16B50/00

Abstract: A system and method for programming DNAzymes to be utilized as programmable drugs, which are active only in the presence of specific input combinations and/or certain conditions.

Abstract translation: 用于编程用作可编程药物的DNA酶的系统和方法，其仅在存在特定输入组合和/或某些条件时是有效的。

公开(公告)号：US08652439B2

公开(公告)日：2014-02-18

申请号：US13164411

申请日：2011-06-20

Applicant: Irun R. Cohen ,  Bracha Rager-Zisman ,  Angel Porgador ,  Johannes Herkel

Inventor： Irun R. Cohen ,  Bracha Rager-Zisman ,  Angel Porgador ,  Johannes Herkel

IPC: A61K51/00 ,  A61K45/00 ,  C12Q1/68

CPC classification number: A61K47/4833 ,  A61K47/646 ,  A61K2039/6043 ,  A61K2039/64 ,  C07K14/005 ,  C12N2770/24122 ,  G01N33/56983 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/394 ,  Y02A50/53 ,  Y02A50/60

Abstract: The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses.

Abstract translation: 本发明提供了包含分离的病毒抗原肽和衍生自HSP60的T细胞表位的合成肽的改进的疫苗。 本发明包括其中肽用作佐剂以及其中肽与病毒抗原共价连接的缀合物的混合物。 已知的合成肽载体p458为合成的病毒表位和类似物提供显着改善的免疫原性。 Ec27是从HSP60衍生的新型肽，其作为混合物或共价缀合物增加了病毒抗原的免疫原性。 一些分离的病毒表位是新的，并且被要求用于诊断以及治疗或预防用途。

公开(公告)号：US20140046065A1

公开(公告)日：2014-02-13

申请号：US14058191

申请日：2013-10-18

Applicant: Yeda Research and Development Co. Ltd.

Inventor： David Milstein ,  Chidambaram Gunanathan

IPC: C07F9/64 ,  C07F9/60

CPC classification number: C07C209/16 ,  B01J31/146 ,  C07B43/04 ,  C07C213/02 ,  C07C2601/14 ,  C07D213/38 ,  C07D305/06 ,  C07D307/52 ,  C07F9/60 ,  C07F9/64 ,  C07F15/0046 ,  C07C211/07 ,  C07C211/17 ,  C07C211/27 ,  C07C217/08 ,  C07C217/58

Abstract: The present invention provides novel ruthenium based catalysts, and a process for preparing amines, by reacting a primary alcohol and ammonia in the presence of such catalysts, to generate the amine and water. According to the process of the invention, primary alcohols react directly with ammonia to produce primary amines and water in high yields and high turnover numbers. This reaction is catalyzed by novel ruthenium complexes, which are preferably composed of quinolinyl or acridinyl based pincer ligands.

公开(公告)号：US08629259B2

公开(公告)日：2014-01-14

申请号：US12309415

申请日：2007-07-22

Applicant: Avigdor Scherz ,  Oksana Shlyk-Kerner ,  Ilan Samish ,  David Kaftan ,  Jorge Dinamarca

Inventor： Avigdor Scherz ,  Oksana Shlyk-Kerner ,  Ilan Samish ,  David Kaftan ,  Jorge Dinamarca

IPC: C12N15/31 ,  C12N15/52 ,  C12N15/82

CPC classification number: C07K14/405 ,  C07K14/195

Abstract: An isolated polynucleotide is provided. The isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide of a Type II reaction center of a photosynthetic organism, the nucleic acid sequence being capable of imparting the type II reaction center with an activity under a temperature range different than that of the type II reaction center endogenous to the photosynthetic organism. Also provided are methods of using the sequences for generating photosynthetic organisms or tailor-made thermotolerance.

Abstract translation: 提供了分离的多核苷酸。 分离的多核苷酸包含编码光合生物的II型反应中心的多肽的核酸序列，所述核酸序列能够使II型反应中心在不同于II型反应的温度范围内具有活性 对光合生物体内生的中心。 还提供了使用序列产生光合生物或定制耐热性的方法。

公开(公告)号：US20130316358A1

公开(公告)日：2013-11-28

申请号：US13982809

申请日：2012-01-31

Applicant: Ami Navon ,  Lior Zelcbuch

Inventor： Ami Navon ,  Lior Zelcbuch

IPC: C12Q1/68

CPC classification number: C12Q1/6853 ,  C12Q2525/161 ,  C12Q2527/143 ,  C12Q2537/143 ,  C12Q2539/105

Abstract: A method of diagnosing a disease in a subject in need thereof is disclosed. The method comprises: (a) linking a plurality of non-contiguous DNA fragments from a sample of the subject to generate a polynucleotide product, the linking being effected by contacting the plurality of non-contiguous DNA fragments with a multiplex overlap-extension primer mix under conditions that allow simultaneous linkage of the DNA fragments and amplification of the polynucleotide product, wherein the primer mix comprises two flanking primers and at least one linker primer; and (b) determining a sequence of the polynucleotide product, wherein the sequence is indicative of the disease.

Abstract translation: 公开了在有需要的受试者中诊断疾病的方法。 该方法包括：（a）将来自受试者样品的多个非连续DNA片段连接以产生多核苷酸产物，所述连接通过使多个非连续DNA片段与多重重叠延伸引物混合物 在允许DNA片段的同时连接和多核苷酸产物的扩增的条件下，其中引物混合物包含两个侧翼引物和至少一个连接体引物; 和（b）确定所述多核苷酸产物的序列，其中所述序列指示所述疾病。